Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aequus PharmaceuticalsAQSZF FCF Yield % is -23.77 as of Jul. 15, 2026. The stock has 6 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Aequus Pharmaceuticals ranks worse than 90.46% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Aequus Pharmaceuticals FCF Yield % Related Terms
Aequus Pharmaceuticals FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AQSZF vs GCAN, STEK, CBSTQ: FCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aequus Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aequus Pharmaceuticals FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aequus Pharmaceuticals's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Aequus Pharmaceuticals's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aequus Pharmaceuticals (AQSZF) has a FCF Yield % of -23.77 as of Jul. 15, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Aequus Pharmaceuticals and its competitors. According to the industry distribution chart, Aequus Pharmaceuticals ranks #910 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 90.5%.
Is Aequus Pharmaceuticals' FCF Yield % too high?
Aequus Pharmaceuticals' current FCF Yield % is -23.77. Based on the distribution chart, Aequus Pharmaceuticals ranks #910 out of 1006 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Aequus Pharmaceuticals' FCF Yield % compare to GCAN and STEK?
According to the Drug Manufacturers industry distribution chart, Aequus Pharmaceuticals ranks #910 out of 1006 companies for FCF Yield %. This places Aequus Pharmaceuticals in the lower half of its industry. The industry median FCF Yield % is 0.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.69, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Aequus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aequus Pharmaceuticals's current FCF Yield % is -23.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aequus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aequus Pharmaceuticals (AQSZF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.01, compared to a current price of $0.00 — trading 74% below its estimated fair value. The current FCF Yield % is -23.77. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Aequus Pharmaceuticals (AQSZF), the current FCF Yield % is -23.77 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products namely Tacrolimus IR and Vistitan.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AQSZF has been successfully added to your 
